Prognostic and pathogenic role of angiopoietin-1 and -2 in pneumonia

American Journal of Respiratory and Critical Care Medicine

Volumn 198, Issue 2, 2018, Pages 220-231

  Gutbier, Birgitt ^a,i   Neuhauß, Anne Kathrin ⁱ   Reppe, Katrin ^a,i   Ehrler, Carolin ⁱ   Santel, Ansgar ^b   Kaufmann, Jörg ^b   Scholz, Markus ^c   Weissmann, Norbert ^d   Morawietz, Lars ^e   Mitchell, Timothy J ^f   Aliberti, Stefano ^g   Hippenstiel, Stefan ^j   Suttorp, Norbert ^h   Witzenrath, Martin ^a,h,i  

^a HUMBOLDT UNIVERSITY   (Germany)

^b Silence Therapeutics GmbH   (Germany)

^c UNIVERSITY OF LEIPZIG   (Germany)

^d JUSTUS LIEBIG UNIVERSITY   (Germany)

^e Pathology Laboratory   (Germany)

^f UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^g UNIVERSITY OF MILAN   (Italy)

^h CAPNETZ STIFTUNG   (Germany)

ⁱ CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^j NONE

more..

Author keywords

Acute respiratory distress syndrome; Endothelial permeability; Pneumolysin; Streptococcus pneumoniae

Indexed keywords

ANGIOPOIETIN 1; ANGIOPOIETIN 2; BILIRUBIN; C REACTIVE PROTEIN; CREATININE; MESSENGER RNA; PNEUMOLYSIN; PROCALCITONIN;

AGED; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL PNEUMONIA; BLOOD VESSEL PERMEABILITY; COMMUNITY ACQUIRED PNEUMONIA; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; INTENSIVE CARE; LENGTH OF STAY; LUNG PARENCHYMA; MAJOR CLINICAL STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; STREPTOCOCCUS PNEUMONIA; SURVIVAL TIME; UMBILICAL VEIN ENDOTHELIAL CELL; BLOOD; DRUG EFFECT; ENDOTHELIUM CELL; HOST PATHOGEN INTERACTION; INFLAMMATION; LUNG; PATHOPHYSIOLOGY;

ANGIOPOIETIN-1; ANGIOPOIETIN-2; ENDOTHELIAL CELLS; HOST-PATHOGEN INTERACTIONS; HUMANS; INFLAMMATION; LUNG; PNEUMONIA, PNEUMOCOCCAL; PROGNOSIS;

EID: 85050076816     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201708-1733OC     Document Type: Article

References (50)

1. Mizgerd JP. Acute lower respiratory tract infection. N Engl J Med 2008; 358:716–727.
2. World Health Organiation. The top 10 causes of death worldwide. Fact Sheet No. 310 [2013; updated July 2013]. Available from: http://who.int/mediacentre/factsheets/fs310/en/index.html.
3. Matthay MA, Ware LB, Zimmerman GA. The acute respiratory distress syndrome. J Clin Invest 2012;122:2731–2740.
4. Eklund L, Saharinen P. Angiopoietin signaling in the vasculature. Exp Cell Res 2013;319:1271–1280.
5. Thomas M, Augustin HG. The role of the angiopoietins in vascular morphogenesis. Angiogenesis 2009;12:125–137.
6. Fiedler U, Reiss Y, Scharpfenecker M, Grunow V, Koidl S, Thurston G, et al. Angiopoietin-2 sensitizes endothelial cells to TNF-a and has a crucial role in the induction of inflammation. Nat Med 2006;12: 235–239.
7. Parikh SM, Mammoto T, Schultz A, Yuan HT, Christiani D, Karumanchi SA, et al. Excess circulating angiopoietin-2 may contribute to pulmonary vascular leak in sepsis in humans. PLoS Med 2006; 3:e46.
8. Thurston G, Rudge JS, Ioffe E, Zhou H, Ross L, Croll SD, et al. Angiopoietin-1 protects the adult vasculature against plasma leakage. Nat Med 2000;6:460–463.
9. Mofarrahi M, Nouh T, Qureshi S, Guillot L, Mayaki D, Hussain SN. Regulation of angiopoietin expression by bacterial lipopolysaccharide. Am J Physiol Lung Cell Mol Physiol 2008;294:L955–L963.
10. David S, Ghosh CC, Mukherjee A, Parikh SM. Angiopoietin-1 requires IQ domain GTPase-activating protein 1 to activate Rac1 and promote endothelial barrier defense. Arterioscler Thromb Vasc Biol 2011;31:2643–2652.
11. Mammoto T, Parikh SM, Mammoto A, Gallagher D, Chan B, Mostoslavsky G, et al. Angiopoietin-1 requires p190 RhoGAP to protect against vascular leakage in vivo. J Biol Chem 2007;282:23910–23918.
12. Sako K, Fukuhara S, Minami T, Hamakubo T, Song H, Kodama T, et al. Angiopoietin-1 induces Kruppel-like factor 2 expression through a phosphoinositide 3-kinase/AKT-dependent activation of myocyte enhancer factor 2. J Biol Chem 2009;284:5592–5601.
13. Scharpfenecker M, Fiedler U, Reiss Y, Augustin HG. The Tie-2 ligand angiopoietin-2 destabilizes quiescent endothelium through an internal autocrine loop mechanism. J Cell Sci 2005;118:771–780.
14. Gamble JR, Drew J, Trezise L, Underwood A, Parsons M, Kasminkas L, et al. Angiopoietin-1 is an antipermeability and anti-inflammatory agent in vitro and targets cell junctions. Circ Res 2000;87:603–607.
15. Fiedler U, Scharpfenecker M, Koidl S, Hegen A, Grunow V, Schmidt JM, et al. The Tie-2 ligand angiopoietin-2 is stored in and rapidly released upon stimulation from endothelial cell Weibel-Palade bodies. Blood 2004;103:4150–4156.
16. Gallagher DC, Parikh SM, Balonov K, Miller A, Gautam S, Talmor D, et al. Circulating angiopoietin 2 correlates with mortality in a surgical population with acute lung injury/adult respiratory distress syndrome. Shock 2008;29:656–661.
17. Lymperopoulou K, Velissaris D, Kotsaki A, Antypa E, Georgiadou S, Tsaganos T, et al. Angiopoietin-2 associations with the underlying infection and sepsis severity. Cytokine 2015;73:163–168.
18. Ricciuto DR, dos Santos CC, Hawkes M, Toltl LJ, Conroy AL, Rajwans N, et al. Angiopoietin-1 and angiopoietin-2 as clinically informative prognostic biomarkers of morbidity and mortality in severe sepsis. Crit Care Med 2011;39:702–710.
19. Agrawal A, Matthay MA, Kangelaris KN, Stein J, Chu JC, Imp BM, et al. Plasma angiopoietin-2 predicts the onset of acute lung injury in critically ill patients. Am J Respir Crit Care Med 2013;187:736–742.
20. Gutbier B, Reppe K, Neuhauß A-K, Kaufmann J, Weissmann N, Morawitz L, et al. Role of angiopoietins Ang-1 and Ang-2 for the development of acute lung injury in pneumococcal pneumonia [abstract]. Am J Respir Crit Care Med 2011;183:A1982.
21. Neuhaus A-K, Gutbier B, Friedemann T, Gunther A, Stoll D, Weismann N, et al. Angiopoietins: possible biomarkers in severe pneumonia? [abstract]. Eur Respir J 2012;40(Suppl 56):P830.
22. Welte T, Suttorp N, Marre R. CAPNETZ: Community-acquired Pneumonia Competence Network. Infection 2004;32:234–238.
23. Bauer TT, Ewig S, Marre R, Suttorp N, Welte T; CAPNETZ Study Group. CRB-65 predicts death from community-acquired pneumonia. J Intern Med 2006;260:93–101.
24. Ahnert P, Creutz P, Scholz M, Schütte H, Engel C, Hossain H, et al.; PROGRESS Study Group. PROGRESS: prospective observational study on hospitalized community acquired pneumonia. BMC Pulm Med 2016;16:108.
25. Schnittler HJ, Wilke A, Gress T, Suttorp N, Drenckhahn D. Role of actin and myosin in the control of paracellular permeability in pig, rat and human vascular endothelium. J Physiol 1990;431:379–401.
26. Giaever I, Keese CR. A morphological biosensor for mammalian cells. Nature 1993;366:591–592.
27. Mitchell TJ, Walker JA, Saunders FK, Andrew PW, Boulnois GJ. Expression of the pneumolysin gene in Escherichia coli: rapid purification and biological properties. Biochim Biophys Acta 1989; 1007:67–72.
28. Santel A, Aleku M, Keil O, Endruschat J, Esche V, Fisch G, et al. A novel siRNA–lipoplex technology for RNA interference in the mouse vascular endothelium. Gene Ther 2006;13:1222–1234.
29. Witzenrath M, Gutbier B, Hocke AC, Schmeck B, Hippenstiel S, Berger K, et al. Role of pneumolysin for the development of acute lung injury in pneumococcal pneumonia. Crit Care Med 2006;34:1947–1954.
30. Kolditz M, Ewig S, Höffken G. Management-based risk prediction in community-acquired pneumonia by scores and biomarkers. Eur Respir J 2013;41:974–984.
31. Ewig S, Birkner N, Strauss R, Schaefer E, Pauletzki J, Bischoff H, et al. New perspectives on community-acquired pneumonia in 388 406 patients: results from a nationwide mandatory performance measurement programme in healthcare quality. Thorax 2009;64: 1062–1069.
32. Loke YK, Kwok CS, Niruban A, Myint PK. Value of severity scales in predicting mortality from community-acquired pneumonia: systematic review and meta-analysis. Thorax 2010;65:884–890.
33. Chalmers JD, Singanayagam A, Akram AR, Mandal P, Short PM, Choudhury G, et al. Severity assessment tools for predicting mortality in hospitalised patients with community-acquired pneumonia: systematic review and meta-analysis. Thorax 2010;65: 878–883.
34. Chalmers JD, Mandal P, Singanayagam A, Akram AR, Choudhury G, Short PM, et al. Severity assessment tools to guide ICU admission in community-acquired pneumonia: systematic review and meta-analysis. Intensive Care Med 2011;37:1409–1420.
35. Calfee CS, Gallagher D, Abbott J, Thompson BT, Matthay MA; NHLBI ARDS Network. Plasma angiopoietin-2 in clinical acute lung injury: prognostic and pathogenetic significance. Crit Care Med 2012;40: 1731–1737.
36. Palud A, Parmentier-Decrucq E, Pastre J, De Freitas Caires N, Lassalle P, Mathieu D. Evaluation of endothelial biomarkers as predictors of organ failures in septic shock patients. Cytokine 2015;73:213–218.
37. Takahashi T, Asano Y, Shibata S, Tada Y, Sato S. Serum angiopoietin-2 level as a potential biomarker in psoriasis vulgaris. J Dermatol 2017; 44:205–206.
38. Calfee CS, Janz DR, Bernard GR, May AK, Kangelaris KN, Matthay MA, et al. Distinct molecular phenotypes of direct vs indirect ARDS in single-center and multicenter studies. Chest 2015;147:1539–1548.
39. Waterer G. Severity scores and community-acquired pneumonia: time to move forward. Am J Respir Crit Care Med 2017;196:1236–1238.
40. Schnürch H, Risau W. Expression of Tie-2, a member of a novel family of receptor tyrosine kinases, in the endothelial cell lineage. Development 1993;119:957–968.
41. Cockeran R, Anderson R, Feldman C. The role of pneumolysin in the pathogenesis of Streptococcus pneumoniae infection. Curr Opin Infect Dis 2002;15:235–239.
42. Bhandari V, Choo-Wing R, Lee CG, Zhu Z, Nedrelow JH, Chupp GL, et al. Hyperoxia causes angiopoietin 2–mediated acute lung injury and necrotic cell death. Nat Med 2006;12:1286–1293.
43. Kim I, Kim JH, Ryu YS, Liu M, Koh GY. Tumor necrosis factor-a upregulates angiopoietin-2 in human umbilical vein endothelial cells. Biochem Biophys Res Commun 2000;269:361–365.
44. Lüttge M, Fulde M, Talay SR, Nerlich A, Rohde M, Preissner KT, et al. Streptococcus pneumoniae induces exocytosis of Weibel-Palade bodies in pulmonary endothelial cells. Cell Microbiol 2012;14: 210–225.
45. Lucas R, Sridhar S, Rick FG, Gorshkov B, Umapathy NS, Yang G, et al. Agonist of growth hormone–releasing hormone reduces pneumolysin-induced pulmonary permeability edema. Proc Natl Acad Sci USA 2012;109:2084–2089.
46. Lucas R, Yang G, Gorshkov BA, Zemskov EA, Sridhar S, Umapathy NS, et al. Protein kinase C-a and arginase I mediate pneumolysin-induced pulmonary endothelial hyperpermeability. Am J Respir Cell Mol Biol 2012;47:445–453.
47. Hashimoto T, Pittet JF. Angiopoietin-2: modulator of vascular permeability in acute lung injury? PLoS Med 2006;3:e113.
48. Mei SH, McCarter SD, Deng Y, Parker CH, Liles WC, Stewart DJ. Prevention of LPS-induced acute lung injury in mice by mesenchymal stem cells overexpressing angiopoietin 1. PLoS Med 2007;4:e269.
49. Witzenbichler B, Westermann D, Knueppel S, Schultheiss HP, Tschope C. Protective role of angiopoietin-1 in endotoxic shock. Circulation 2005;111:97–105.
50. Li X, Stankovic M, Bonder CS, Hahn CN, Parsons M, Pitson SM, et al. Basal and angiopoietin-1–mediated endothelial permeability is regulated by sphingosine kinase-1. Blood 2008;111:3489–3497.